On 9 November 2026, Sandoz announced that it has launched Owozy™, a generic version of Novo Nordisk’s Ozempic® (semaglutide), in Brazil. This is the first semaglutide launch for Sandoz worldwide.
Owozy™ was developed by Malta-headquartered Adalvo and was approved in Brazil on 29 July 2026 for the treatment of type 2 diabetes. According to Sandoz, Owozy™ is among the earliest new semaglutide treatment options available in Brazil, which has a GLP-1 market estimated to be worth USD 2.7 billion, with more than 16.5 million Brazilians living with diabetes.
The launch of Owozy™ in Brazil follows the approval of Sandoz’s generic semaglutide in Canada in September 2026, which is expected to launch by the end of 2026.
A number of generic semaglutide products have now been launched around the world. In March 2026, Dr Reddy’s, Zydus, Alkem, Sun Pharma and Glenmark launched generic semaglutide products on the Indian market, following the expiry of Novo Nordisk’s core Indian patent for semaglutide. Generic semaglutide products were also launched in Canada in May 2026 by Apotex and Dr Reddy’s. Sun Pharma’s generic semaglutide injection was approved in South Africa (announced 15 July 2026), with launch following shortly thereafter.
Apotex received the first US FDA Tentative Approval for its generic semaglutide ANDA in April 2026, giving it an opportunity to be one of the first to launch generic Ozempic® in the US following expiry of Novo Nordisk’s exclusivity/patents. Novo Nordisk has sued Apotex in the US in relation to generic Rybelsus®, Ozempic® and Wegovy®, alleging patent infringement, with the three cases being consolidated in June 2026. Novo Nordisk also commenced Hatch Waxman litigation against Cipla in July 2026 in relation to generic semaglutide products.